GSK2336805

DRUG3 trials

Sponsors

GlaxoSmithKline, Janssen R&D Ireland

Conditions

Chronic Hepatitis CHepatitis CHepatitis C, Chronic

Phase 1

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

CompletedNCT01827657

GlaxoSmithKlineHepatitis C

Start: 2013-05-28End: 2014-03-20Updated: 2017-06-14

Phase 2

Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

CompletedNCT01439373

GlaxoSmithKlineHepatitis C, Chronic

Start: 2011-07-07End: 2011-12-05Updated: 2017-12-11

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

CompletedNCT01724086

Janssen R&D IrelandChronic Hepatitis C

Start: 2012-10-31End: 2014-12-31Updated: 2016-01-11

Related Papers

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology Journal2017-05-314 citations

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

2017-02-104 citations

A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of <scp>GSK</scp>2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects

Liver International2013-10-118 citations